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(b) Abstract and key words 
 
ABSTRACT (250 words including headings) 
Issues: Non-injectable naloxone formulations are being developed for opioid overdose 
reversal, but only limited data have been published in the peer-reviewed domain. Through 
examination of a hitherto-unsearched database, we expand public knowledge of non-
injectable formulations, tracing their development and novelty, with the aim to describe and 
compare their pharmacokinetic properties. 
Approach: 1) The PatentScope database of the World Intellectual Property Organization 
was searched for relevant English-language patent applications; 2) Pharmacokinetic data 
were extracted, collated and analysed. 3) PubMed was searched using Boolean search 
query “(nasal OR intranasal OR nose OR buccal OR sublingual) AND naloxone AND 
pharmacokinetics”.  
Key Findings: 522 PatentScope and 56 PubMed records were identified: 3 published 
international patent applications and 5 peer-reviewed papers met eligibility criteria. 
Pharmacokinetic data were available for intranasal, sublingual, and reference routes 
(intramuscular, intravenous, subcutaneous). Highly concentrated formulations (10-40mg/ml) 
had been developed and tested. Sublingual bioavailability was very low (F=1%; relative to 
intravenous). Non-concentrated intranasal spray (1mg/ml; 1ml per nostril) had low 
bioavailability (F=11%). For concentrated intranasal spray formulations (≥10mg/ml), 
bioavailability ranges were F=21-42% and FIM=26-57% (relative to intramuscular), with peak 
naloxone concentrations (dose-adjusted Cmax=0.8-1.7ng/ml) reached in 19-30 minutes 
(tmax).  
Implications: Exploratory analysis identified intranasal bioavailability as associated 
positively with dose and negatively with volume.  
Conclusion: PatentScope is a valuable data source but rarely explored. From data 
integration from different naloxone patent applications, we find consistent direction of 
development of intranasal sprays to high-concentration, low-volume formulations with 
bioavailability in the 20-60% range. These have potential to deliver a therapeutic dose in 
0.1ml volume. 
Key words: intranasal, naloxone, pharmacokinetics, opioids, drug overdose  
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(c) Text 
Introduction 
On November 18, 2015, the US Food and Drug Administration (FDA) gave regulatory 
approval for a concentrated intranasal (IN) naloxone spray by Adapt Pharma (1), which 
constitutes the first-ever licensed non-injectable naloxone product. Regulatory approval in 
Canada followed in October 2016 (2). The FDA and Health Canada decisions have opened 
up the possibility, for North America at least, of wider access to naloxone in light of the rising 
death toll from opioid overdoses (3). At an estimated 106,000 deaths per annum (4), opioid 
overdose deaths are also a growing international public health concern. To date, globally, no 
other non-injectable naloxone formulation has been licensed.    
Effective non-injectable naloxone products would remove the risk of needle-stick injury in 
medical and community settings. Non-injectable naloxone may offer a particular 
implementation advantage for take-home naloxone (THN) programs, i.e. the pre-placement 
of naloxone kits with opioid users, families, peers, community police, and staff at treatment 
services, drop-in centers and hostels, where it would likely reduce regulatory obstacles and 
the current requirement of training laypersons in needle-and-syringe assembly and 
administration (5). First proposed in 1996 (6), THN has increasingly been introduced in the 
past decade, and recent WHO guidelines and a UN declaration have called for naloxone 
access for “anyone likely to witness an overdose” (7, 8). In response, the FDA, the US 
Centers for Disease Control and Prevention (CDC), National Institute on Drug Abuse (NIDA), 
and Office of the Assistant Secretary for Health and Human Services (HHS) sponsored a 
2012 stakeholder meeting where key criteria for any novel non-injectable naloxone product 
were proposed (9, 10).  
According to the FDA (9), one or more standardized doses of a novel non-injectable 
naloxone formulation would need to result in plasma naloxone levels (i.e. area under the 
curve; AUC) comparable to a parenteral dose of at least 0.4mg. If the bioavailability (F = 
“absolute bioavailability”, relative to intravenous; FIM = “relative bioavailability”, relative to 
intramuscular) of the new product compared with the approved injection is low, then it is 
unclear if adequate efficacy can be reached. Vice versa, if the bioavailability is unexpectedly 
high, then this may have implications for the safety profile of the novel formulation. 
Furthermore, the bioavailability compared with injection would need to be reasonably 
constant between different individuals. In the emergency situation of opioid overdose, 
naloxone needs to be absorbed rapidly. Absorption would thus need to be at least as rapid 
as intramuscular injection, whereby onset of effect starts within 3 to 7 minutes of 
administration (8). The key pharmacokinetic (PK) parameters for a non-injectable naloxone 
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formulation are typically the maximum observed plasma concentration (Cmax) and the time 
from dosing to peak concentration (Tmax), in addition to bioavailability. 
A recent systematic review (11) applied the FDA criteria to the peer-reviewed literature and 
identified three candidate routes of administration for injection-free naloxone delivery: IN, 
sublingual, and buccal. However, at the time of the FDA approval of the first nasal spray, no 
results from clinical trials on the new nasal spray were published, and human PK data were 
only reported in one peer-reviewed publication for an improvised IN naloxone spray 
formulation (2mg/5ml), with extremely low bioavailability (F=4%) (12). While improvised IN 
spray devices (administered by attaching a mucosal atomiser device to a pre-filled 2mg/2ml 
naloxone syringe) are commonly used in take-home naloxone programs in some countries 
(CDC) and a significant number of overdose reversals have been reported (13, 14). 
uncertainties regarding their efficacy have been considered  and primarily concern their 
potential non-response rate and lack of safety data (15-17). 
Time lag between research and development activity in the pharmaceutical industry and the 
publication of relevant data in the peer-reviewed literature is not new: Indeed, more than five 
decades ago, the discovery and original synthesis of naloxone was first reported in a 1961 
patent application (18) before a conference abstract (19) and a full journal article (20) 
followed in subsequent years.  
This exploratory review attempts to close the existing gap in the literature by examining 
published international patent applications of non-injectable naloxone formulations and 
contributory PK data. The aims are threefold: 1) to trace the concept and product 
development by route of administration; 2) to describe the non-injectable naloxone 
formulations for which human in vivo data are available; 3) to compare human PK data 
reported in the patent applications. 
Methods 
A three-stage approach has been taken.  
Stage 1:  
The PatentScope database of the World Intellectual Property Organization (WIPO), which 
contains 58 million patent documents including 3 million published international patent 
applications (21), was searched for patent applications for non-injectable naloxone 
formulations. PatentScope was searched for English-language patent applications 
(“Language: EN”) that were registered with any international patent office (“Office(s): all”) 
and contained the search term “naloxone” within their First Page (default). Only patent 
applications for non-injectable naloxone that contained human PK data were eligible for 
inclusion in the analysis (Aims 2 & 3).  
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Stage 2 
The pharmaceutical properties of the non-injectable naloxone formulations and human PK 
data were extracted from patent applications and summarized. To improve comparability 
between formulations, dose-adjusted values per 1mg were generated.  
Stage 3 
To supplement and cross-check the data obtained in Stages 1 and 2, we also searched 
PubMed for human PK data for non-injectable naloxone using the Boolean search query 
“(nasal OR intranasal OR nose OR buccal OR sublingual) AND naloxone AND 
pharmacokinetics” (see Table S1 for search protocol). These three routes of administration 
were chosen based on the systematic review (11). 
For all three stages, R.M. and Ø.D.G. conducted the PatentScope and PubMed searches, 
assessed retrieved records for eligibility, and extracted relevant information under 
supervision of the senior authors (O.D., J.S.). 
 
*** Insert Figures 1 & 2 about here *** 
 
Results 
Stage 1: 
A PRISMA flow diagram of the selection process of patent applications is shown in Figure 1. 
522 PatentScope records were identified using the search term “naloxone” for front-page 
matches. At this stage, a cross-check was made for known patent applications, and it was 
found that no entry for the FDA-approved Adapt IN spray product had been captured. We 
thus additionally searched PatentScope for “Adapt OR Lightlake”-related entries. (In late 
2014, Adapt Pharma had bought the global license from Lightlake Therapeutics Inc. to 
develop and commercialize their IN naloxone spray (22).) After matching for the search term 
“Lightlake” (front-page search, English language, all patent offices), this additional search 
yielded five patent applications, which had not been captured using the search term 
“naloxone” because Lightlake had not included the word ‘naloxone’ on the front page. 
Consequently, we manually added these five Lightlake patent applications (n.b. in the 
following, we denote these as ‘Lightlake’ unless we refer directly to the licensed Adapt nasal 
spray product).  
Of the 47 records that remained after removing 480 irrelevant records, 10 were excluded 
based on their abstract (e.g. active ingredient other than naloxone). The remaining 37 
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records were downloaded for full-text review and screened for human PK data. Of the 14 
patent applications that contained relevant PK data, 11 were excluded for the following 
reasons: 5 reported only animal data, and 6 were duplicates (earlier or later versions of 
patents containing the same PK data but different patent claims or country of publication). 
Three published international patent applications were identified as eligible for inclusion: 
WO/2015/136373, WO/2015/095644, and WO/2012/156317.  
A timeline of the publication of all 37 patent applications (including excluded records) is 
provided in Table S2 of the Online Appendix. The timeline shows that the concept of non-
injectable naloxone (drops, spray, solution, suspension, ointment or gel) was first being 
explored at the University of Kentucky, with first animal data reported in 1982. The 1990s 
showed no activity for IN naloxone except for the patent application of a spray dispenser by 
Britannia Pharmaceuticals in 2000 (n.b. the same spray device as in the 2015 FDA-
approved Adapt naloxone spray). In 2005, an IN naloxone powder was proposed by the 
Chinese PLA Academy of Military Science. The first human PK data for IN naloxone were 
filed by Euro-Celtique in 2012 (WO/2012/156317).    
The first patent application describing the concept of sublingual or buccal naloxone was 
published by the Israeli company Pentach Pharmaceuticals in 2004, and patent applications 
covering sublingual naloxone (spray, dripping pills) by two Beijing-based companies followed 
in 2007 and 2011. In 2012, Euro-Celtique included sublingual PK data in its patent 
application on concentrate IN naloxone spray (see above). In June 2015, INSYS Pharma 
submitted two patent applications for sublingual naloxone spray (no PK data) and was 
granted FDA fast-track review later that year (23).  
 
*** Insert Table 1 about here *** 
Stage 2: Description of intranasal pharmacokinetic data 
We now describe the IN PK data reported in the published international patent applications 
WO/2015/136373 (Lightlake Therapeutics), WO/2015/095644 (AntiOp), and 
WO/2012/156317 (Euro-Celtique). The pharmaceutical properties of the naloxone 
formulations tested by AntiOp (10mg/ml) and Lightlake (10mg/ml; 20mg/ml; 40mg/ml) are 
described in detail in Table S4 of the Online Appendix; Euro-Celtique only reported the 
concentration of their formulations (20mg/ml, 40mg/ml Naloxone HCl). 
All PK data were obtained using crossover study designs, though sample sizes differed from 
7 to 35 subjects per arm. For a full summary of the PK data (including reference routes), 
please see Table 1.  
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AntiOp described two studies, which are hereby referred to as ‘Trial 1 (Pilot’) and ‘Trial 2’. 
AntiOp tested a 10mg/ml IN formulation administered as 0.1ml into one and two nostrils, as 
well as 0.2ml per nostril (0.1+0.1ml with 5-minute interval). Trial 1 (Pilot) also tested non-
concentrate 1mg/ml naloxone, with mucosal atomizer device (MAD) attached to a syringe, 
thus replicating the improvised IN naloxone distributed off-label in several countries.  
Lightlake presented results from two studies: Study 1 assessed a 10mg/ml formulation, 
whereas Study 2 tested 20mg/ml and 40mg/ml formulations, all administered as 0.1ml into 
one and two nostrils (total volume: 0.2ml). 
Euro-Celtique tested IN doses of 8mg (0.2ml per nostril; 20mg/ml concentration) and 16mg 
(0.2ml per nostril; 40mg/ml concentration). Euro-Celtique also included a sublingual arm 
(16mg/ml solution), but this route is not described here in detail, as its absolute bioavailability 
was only 1%.  
For IN administration, we present F as well as FIM, as neither measure was reported across 
all three patent applications. (Euro-Celtique only provided F, whereas the more recent 
AntiOp and Lightlake patent applications reported FIM in accordance with guidance from the 
FDA). 
F: For the Euro-Celtique data, we calculated F values of 22% (20mg/ml, administered as 
0.2ml per nostril) and 21% (40mg/ml; 0.2ml per nostril) using AUC0-∞ data listed in the PK 
data appendix of the patent application. We were unable to obtain the higher F values of 
32% (20mg/ml formulation) and 27% (40mg/ml) which Euro-Celtique cited in-text for lower 
doses (1.2 and 1.6mg, dose-adjusted from 8 and 16mg) in the body of the patent application. 
AntiOp only reported FIM, but included an IV reference in Trial 1 (Pilot), which allowed us to 
determine the following F-values for comparison: 36% (0.1ml, one nostril only) and 42% 
(0.1ml per nostril) for the 10mg/ml formulation, and 11% for non-concentrate naloxone 
(1mg/ml per nostril). 
FIM: Lightlake achieved the highest FIM values across all three patent applications, with 0.1ml 
of the 10mg/ml formulation administered into both nostrils (FIM=57%). FIM was lower (48%), 
when the volume of the same formulation was doubled (0.2ml per nostril). For the 20mg/ml 
formulation, FIM was 54% (0.1ml, one nostril only) and 55% (0.1ml per nostril). The 40mg/ml 
formulations achieved 49% and 45% when administered into one and both nostrils, 
respectively. AntiOp reported the following FIM values for a 10mg/ml formulation: 34% (0.1ml, 
one nostril only), 31-39% (0.1ml per nostril), and 26% (0.1ml per nostril, with re-
administration after 5 minutes; i.e. total volume of 0.2ml per nostril). Non-concentrate 
naloxone (1mg/ml per nostril) had a FIM of 10%.  
t1/2: The terminal half-life (t1/2) is the time it takes for the blood concentration of a 
pharmacological agent to decrease by 50%, which usually translates into the loss of half of 
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its pharmacologic activity. Euro-Celtique reported the longest terminal half-lives (t1/2) for IN 
administration, with 9.1 (40mg/ml) and 9.5 hours (20mg/ml), though data were only available 
for 4 subjects. In the AntiOp and Lightlake patent applications, t1/2 fell in the range of 1.2–2.1 
hours.  
tmax: IN tmax was 0.27 hours (i.e. 16 minutes) for non-concentrated spray (AntiOp, 1mg/ml, 
1ml per nostril) and ranged from 0.31 to 0.50 hours (i.e. 19-30 minutes; AntiOp 10mg/ml, 
0.1ml into one nostril and Lightlake 40mg/ml, 0.1ml into one nostril) across concentrated 
spray formulations.  
AUC & Cmax: Dose-adjusted Cmax values (per mg) were highest for the Lightlake 20mg/ml 
formulation administered as 0.1ml per nostril (Cmax=1.66ng/ml). The same treatment arm 
achieved AUC0-∞=2.48ng*h/ml. The Euro-Celtique 20mg/ml formulation reached the highest 
AUC0-∞ value (2.76ng*h/ml) and a per mg Cmax of 1.60ng/ml. The 1mg/ml non-concentrate 
AntiOp treatment (administered as 1ml per nostril) had the lowest values (AUC0-∞
=0.45ng*h/ml; Cmax=0.27ng/ml). 
Additional exploratory analyses: In order to examine the potential influence of spray 
concentration on IN absorption, we plotted AUC, Cmax, and tmax values against volume 
(adjusted by dose for AUC and Cmax) and dose (see Figure 3). For both AUC and Cmax, the 
plots indicate a positive association with dose and a negative association with volume of the 
IN spray. The graphs do not suggest a clear association for tmax. 
 
*** Insert Figure 3 about here *** 
Stage 3: 
The PubMed search generated 56 matches, with zero duplicates (see Figure 2 for PRISMA 
diagram). 46 papers were excluded based on title and abstract (no primary research data 
from human-subject naloxone studies). 
The ten remaining records were then downloaded for full text, with five papers excluded for 
the following reasons: one was a review article, and four did not include naloxone PK data 
(see Table S3 for list of excluded studies). The remaining eligible five papers included 
human PK data in two papers for IN naloxone (12, 24) and three papers for sublingual 
naloxone (25-27). None of the papers contained human PK data for buccal naloxone. 
Divergent bioavailability values have been reported for IN naloxone. One healthy volunteers 
study (n=6) assessed a non-concentrate formulation of IN naloxone (2mg/5ml) and reported 
an absolute bioavailability of only 4%, which the authors attributed as possibly due to the 
dilute solution (and high volume) used (12). Higher absorption was reported in a study (24) 
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with recreational prescription opioid users (n=10) where absolute bioavailability of IN 
administration of crushed buprenorphine/naloxone (4:1 ratio) of two concentrations (0.5mg, 
2mg naloxone) was 24% and 30%, respectively.   
Systemic uptake after sublingual naloxone administration was generally found to be low. In 
one healthy volunteers study, naloxone doses of 1.4mg and 2mg were administered in 
combination with buprenorphine, resulting in a median tmax of 0.8h and peak naloxone 
plasma concentrations below 0.4ng/ml for both doses (26). A second study in non-
dependent opioid users (n=8) (27) assessed escalating naloxone doses (1mg, 2mg, 4mg) 
and found that dose-effect comparisons were impossible, as many naloxone plasma 
concentrations were below the level of quantification (0.050ng/ml). The highest individual 
AUC reported was 0.55ng*h/ml.  
A third study (25) suggested that sublingual naloxone bioavailability is negatively associated 
with healthy liver functioning. A sublingual 0.5mg naloxone tablet (in combination with 2mg 
buprenorphine) was administered to forty-three subjects stratified by hepatic impairment 
(mild, moderate, or severe), HCV diagnosis without hepatic impairment, and healthy 
volunteers. Across all groups, the median tmax ranged from 0.8-1.1 hours, with mean t1/2 from 
1.9-5.5 hours. However, the AUC0-last data revealed an approximate 3 to 14-fold increase in 
total naloxone exposure in subjects with moderate and severe hepatic impairment. Likewise, 
the naloxone Cmax was 3 to 11-times higher in subjects with hepatic impairment.  
 
Discussion 
Human PK data for purpose-made non-injectable naloxone formulations had not been 
reported in peer-reviewed scientific papers at the time of the FDA-approval of the first IN 
naloxone spray (28). However, published international patent applications by the companies 
AntiOp, Euro-Celtique and Lightlake contain data on concentrated sublingual and IN spray 
formulations in the range 10-40mg/ml. Through integration of data from WIPO PatentScope 
and scientific publications retrieved via PubMed, this exploratory review charts R&D activity 
over the past two decades (particularly 2012-present) and provides an assessment of the 
current status of non-injectable naloxone development relative to pre-defined regulatory 
criteria (9, 10). 
Statement of principal findings 
Across all concentrate IN naloxone formulations, bioavailability was 21-42% relative to IV 
and 26-57% relative to IM. We plotted AUC0-∞-and Cmax values and found a moderately 
linear relationship with dose (higher dose  higher AUC0-∞, Cmax) and a negative association 
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for volume (lower volume  higher AUC0-∞, Cmax). The highest IN bioavailability (FIM=57%) 
was reached when 0.1ml of a 10mg/ml formulation was administered into both nostrils. For 
the same formulation, FIM decreased to 48% when volume doubled to 0.2ml per nostril. 
Volume clearly matters. Also, dose-concentration linearity is evident. We identify the 
importance of (low) volume with IN bioavailability drastically lower (F=11%) when a non-
concentrate formulation of 1mg/ml was administered into both nostrils. This confirms 
previous reports of low bioavailability (F=4%) for dilute IN spray (0.4mg/ml) (12).  
Sublingual naloxone administration of a concentrate solution (16mg/ml) had very low 
bioavailability (F=1%). This is below the range of 7-9% identified by Chiang et al. in their 
review of sublingual buprenorphine-naloxone formulations (29). We conclude that sublingual 
is unlikely to be a route of administration of clinical value. 
Strengths and weaknesses of the review 
This is the first review of non-injectable concentrate naloxone formulations in the peer-
reviewed literature. It includes examination of public-domain information from patent 
applications. A core strength of this exploratory review lies in the integration of empirical 
evidence from PubMed and WIPO PatentScope databases, capturing both academic and 
pharmaceutical industry advances in the field.  
The validity of our comparison of IN PK data across different patent applications is 
strengthened by the similarity of the IN spray formulations used. While Euro-Celtique only 
disclosed dose concentrations, all formulations all formulations by Lightlake and AntiOp with 
provided PK data are characterized by absence of absorption enhancers (which increase 
membrane permeation) and viscosity-increasing agents (which increase the residence time 
of naloxone to the nasal mucosa and thus contributes to better absorption) (see Table S4 in 
Online Appendix).  
Potential limitations need to be considered. Firstly, not all research and development activity 
leads to registration of intellectual property or to journal publication, and non-significant or 
negative results have low likelihood of getting published.  
Secondly, our exploratory WIPO PatentScope database search was unlikely exhaustive. 
Considering that our search initially failed to capture the Lightlake patent applications, we 
cannot rule out the possibility of other false-negatives. We conducted the default “First Page” 
search, which identified any patent document with the search term (“naloxone”) mentioned 
on its cover page, generating 522 matches. Had we conducted the more comprehensive 
“Full Text” search (“naloxone” mentioned in any full-text patent document), PatentScope 
would have identified over 19,000 matches, which would have exceeded our capacity for 
manual screening. Compared to online literature databases such as PubMed or Embase, the 
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functionality of the PatentScope interface is less advanced, in that users cannot export full 
search results to a citation manager. For every PatentScope entry, we thus had to download 
associated documents individually to assess eligibility for inclusion in our review. We 
considered supplementing our PatentScope search with additional query of all national and 
regional patent offices for which our PatentScope “naloxone” search had yielded relevant 
entries (Canada, China, European Union, Germany, Great Britain, Israel, Russia, Singapore, 
South Africa, United States; see Online Supplement 2). However, we concluded that this 
was not feasible due to their different search and output formats that are not always 
compatible with PatentScope: for instance, the British online database Ipsum of the UK 
Intellectual Property office only permits search by application or publication number (i.e. not 
by keyword, e.g. “naloxone”) (30), and the United States Patent and Trademark Office offers 
two separate search modes: one for patent applications (Patent Application Full-Text and 
Image Database, AppFT) and one for issued patents (Patent Full-Text and Image Database; 
PatFT) (31), whereas PatentScope does not provide such distinction. 
The third limitation concerns the quality of the data retrieved: we did not have access to raw 
data, and our analysis was reliant upon summary data provided by the patent applicants. 
Consequently, the comparability of the PK results was limited by different analytical methods 
and result formats used in the individual studies included in the patent applications (e.g. 
bioavailability reported as F vs. FIM; central tendency expressed as mean vs. median). For 
instance, for no apparent reason, we were unable to replicate the F-values that Euro-
Celtique cited in-text when we used the PK values listed in the data appendix. Similarly, we 
remain uncertain about the actual concentration of the AntiOp formulation (10mg/ml 
Naloxone HCl or 10mg/ml Naloxone HCl dihydrate), which could have affected calculation of 
dose-adjusted values in Table 1. There was also variability in the sampling periods (8-36 
hours), which may have impacted AUC-dependent measures (e.g. F%, FIM%). In terms of 
reliability of the mean values reported in Table 1, it also needs to be borne in mind that the 
crossover studies (which comprised pilot and registration trials) differed substantially in 
sample sizes (7-35 subjects per treatment arm).  
Meaning of the review: Possible mechanisms and implications for clinicians or policymakers 
These findings have multiple implications for clinicians and policymakers. 
IN naloxone: Low spray volume and high concentrations lead to better IN naloxone 
absorption. Concentrated IN naloxone spray is thus a potentially valuable non-injectable 
formulation for opioid overdose reversal. This is likely relevant both in medical settings and 
in the community (THN programmes). This conclusion accords with the first FDA-approval of 
an IN naloxone spray product (1), at 4mg/0.1ml naloxone hydrochloride (i.e. 40mg/ml 
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concentration). However, further examination is required of the full PK curve and the 
resulting clinical effect since, for all doses of the 40mg/ml formulations tested (4-16mg), we 
found Cmax (5.34-18.3ng/ml) was much higher than for intramuscular (IM) references 
(Cmax=0.77-1.05ng/ml). Consequently, while clinical efficacy of concentrated IN sprays is 
likely, there is the risk of inducing acute opioid withdrawal in overdose victims (32). A recent 
qualitative analysis of heroin/opioid overdose reversals found instances of apparent 
excessive naloxone dosing and consequent ‘over-antagonism’, sometimes triggering 
discharge and active further drug-seeking (33). Hepatic impairment also increases naloxone 
bioavailability, particularly relevant when larger fractions of buccal/sublingual or IN naloxone 
are swallowed (25), potentially causing severe distress and adverse events from naloxone 
over-antagonism in dependent patients. 
The poor IN bioavailability of non-concentrated naloxone using the MAD device also raises 
important questions (15-17). From a scientific perspective, how can such low absorbed 
doses be effective if they are indeed succeeding in reversing overdose? Also, the continued 
use of improvised (i.e. dilute) IN naloxone kits needs review.  
Sublingual naloxone: In October 2015, INSYS Therapeutics announced that its sublingual 
naloxone spray (formulation unknown) had been granted fast-track review by the FDA. 
Considering the low bioavailability reported by the Euro-Celtique study, it seems unlikely that 
sublingual naloxone will be clinically useful.  
Unanswered questions and future research 
Unanswered questions around non-injectable naloxone remain. All PK data reported in the 
referenced patent applications were from healthy volunteers. It remains unclear how these 
findings relate to the heroin/opioid users where non-response rates (i.e. response judged by 
ambulance personnel to need supplementary injected dose) around 18–26% have been 
reported for IN naloxone (34, 35). 
Secondly, there are limitations in our current understanding of the pharmacokinetics and 
pharmacodynamics of naloxone. While this review largely focuses on the bioavailability of 
non-injectable naloxone relative to parenteral injection, the absolute naloxone plasma 
concentration range required to reverse opioid overdose remain unknown. This needs 
sorting. Since naloxone is a competitive antagonist, the therapeutic dose will likely differ by 
route of administration alongside inter-individual variability. Moreover, the naloxone dose 
required to reverse the effects of a specific opioid agonist will depend on the opioid agonist 
dose and its pharmacological properties, particularly its potency, duration of action, and 
receptor affinity (36).  
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An ongoing Australian double-blinded randomised clinical trial at the Sydney Medically 
Supervised Injecting Centre (trial ID: ACTRN12611000852954) compares IN (0.8mg/ml) 
versus IM (0.8mg/ml) naloxone treatment and assesses the proportion of suspected opioid 
overdose cases (by treatment group) needing a second naloxone dose (both groups: 
0.8mg/2ml IM) for overdose reversal. The results of this trial will likely shed light on the 
question of therapeutic dose.  
The 2014 WHO guidelines note that a 0.4-0.8mg parenteral naloxone dose is effective in 
most cases to reverse opioid overdose. However, given that the duration of naloxone is 
shorter than that of many opioids, repeat doses of naloxone may need to be given (37). The 
WHO guidelines advise that initial naloxone doses above 0.8mg increase the likelihood of 
significant withdrawal symptoms (8). For any therapeutic drug, dose-related adverse effects 
(i.e. opioid withdrawal symptoms in the case of naloxone) often occur around Cmax (38), 
suggesting that novel naloxone formulations with Cmax above that of a 0.8mg parenteral 
naloxone injection may pose elevated risk of adverse effects. Future studies should 
systematically monitor and assess reports of naloxone-related adverse effects (from the 
medical or community setting) in relation to the naloxone dose and formulation used.  
Thirdly, while the PK data from the patent applications indicated a negative relationship 
between volume and naloxone uptake, they did not allow us to determine a cut-off for IN 
spray volume (volume above which naloxone is lost to pre or post-nasal drip). Definition of 
the maximum volume will affect repeat-administrations of IN naloxone spray. This too needs 
resolution.  
Finally, we present a new analytical method of synthesis of public patent data from the 
WIPO PatentScope database. The limitations discussed above illustrate that this exploratory 
method will require optimization and would benefit from enhanced functionality of the 
PatentScope interface, so that review of a greater volume of patent documents would 
become manageable. A “Patent Crawler” software has been trialed as a search tool that 
combines analysis of medication and patent databases (39). Future open-source editions of 
such software may potentially help academics, clinicians, and members of the general public 
retrieve medication-related information across patent databases and the peer-reviewed 
medical literature. If such open-source software becomes available, we hope that our search 
protocol provided in Table S1 of the Online Appendix will allow researchers to replicate our 
exploratory analysis with added capture capability. When replicating our search in future, 
researchers might also find it helpful to work together with patent experts who will be familiar 
with the functionality of patent databases and the legal language of (the often broad) patent 
claims. 
In future, such syntheses would also be more valuable if data were presented uniformly: this 
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would require investigators of non-injectable naloxone formulations (including 
pharmaceutical companies) to publish their data even if findings are negative (see e.g. 
AllTrials.net) (40). 
 
Conclusions: 
Over the past fifteen years, IN naloxone sprays have been tested in humans, but no product 
was licensed and commercially available until late 2015 (1). With an ongoing epidemic of 
prescription-opioid overdose deaths alongside a more recent rapid rise in heroin deaths, an 
IN naloxone spray is finally available to prevent overdose deaths in opioid users - a target 
population vastly underserved for decades. This first licensed non-injectable naloxone marks 
a significant milestone towards wider naloxone access and more effective prevention of 
opioid overdose deaths. High-concentrate IN naloxone has good bioavailability although, 
thus far, formal product testing has only involved healthy volunteers. It remains possible that 
high-concentrate formulations may provoke naloxone over-antagonism in opioid-dependent 
patients. Options for dose-titration and alternative routes (e.g. buccal) also need exploration. 
We call for proper publication of PK data on naloxone products: only then can there be 
properly informed consideration of different naloxone products by the clinical, policy and 
scientific communities.  
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Table 1 | Pharmacokinetic properties of patent formulations 
          Observed values Dose-adjusted values (permg) 
 
 
Study n Conc. 
(mg/ml) 
Nostrils 
# 
Dose (mg)/ 
volume (ml) 
F% FIM% tmax 
(h) 
t1/2 
(h) 
Cmax   
(ng/ml) 
AUC0-∞ 
(ng*h/ml) 
AUC0-last 
(ng*h/ml) 
Cmax 
(ng/ml) 
AUC0-∞ 
(ng*h/ml) 
AUC0-last 
(ng*h/ml) 
IV AntiOp Trial 1 13 0.4  0.4/1.0   0.03±0.1 1.28±0.2 3.87±2.7 1.67±0.5   9.68a 4.18a  
 Euro-Celtique 11 1  1.0/1.0   0.85±1.6 0.89±0.1e 17.9±29.9 12.6±12.4e 10.5±7.2 17.9a 12.6a 10.5a 
IM AntiOp Trial 1 13 NA  1.0/NA 106a, d  0.33±0.5 1.41±0.3 2.54±1.0 4.43±1.2  2.54a 4.43a  
 AntiOp Trial 2 34 0.4  0.4/1.0   0.17 (0.1, 1.0) 1.38±0.3 1.05±0.4 1.67±0.4  2.63a 4.18a  
 Lightlake 1 14 0.4  0.4/1.0   0.34±0.1 1.21±0.2 0.77±0.2 1.42±0.3 1.38±0.3 1.91a 3.55a 3.45a 
 Lightlake 2 28 0.4  0.4/1.0   0.42 (0.1, 2.0) 1.19b 0.91±0.3 1.83±0.4 1.79±0.4 2.26±0.7 4.57±1.1 4.48a 
SQ AntiOp Trial 1 13 NA  1.0/NA 99a, d 94a, d 0.17±0.3 1.59±0.6 2.72±0.8 4.15±1.1  2.72a 4.15a  
IN AntiOp Trial 1* 13 10 2 2.0/0.2 42a, d 39a, d 0.42±0.3 1.53±0.2 1.95±1.1 3.47±0.8  0.98a 1.74a  
 AntiOp Trial 1* 13 10 1 1.0/0.1 36a, d 34a, d 0.50±0.2 1.41±0.3 0.84±0.5 1.52±0.5  0.84a 1.52a  
 AntiOp Trial 1 7 1 2 2.0/2.0 11a, d 10a, d 0.27±0.1 1.64±0.3 0.53±0.2 0.90±0.2  0.27a 0.45a  
 AntiOp Trial 2* 33 10 2 2.0/0.2  31a, d 0.33 (0.3, 0.8) 1.37±0.3 1.78±1.0 2.63±1.3  0.89a 1.32a  
 AntiOp Trial 2* 35 10 2+2c 4.0/0.4  26a, d 0.42 (0.2, 1.0) 1.41±0.3 3.06±1.6 4.42±2.2  0.77a 1.11a  
 Lightlake 1 14 10 2 2.0/0.2  57 0.33±0.1 1.19±0.1 2.32±1.0 3.44±1.0 3.41±1.0 1.16a 1.72a 1.71 
 Lightlake 1 14 10 2 4.0/0.4  48 0.31±0.1 1.22±0.1 4.55±2.9 5.68±1.6 5.63±1.6 1.14a 1.42a 1.41 
 Lightlake 2 28 20 1 2.0/0.1  54 0.33 (0.3, 1.0) 1.70b 3.11±1.1 4.86±1.5 4.81±1.5 1.56±0.6 2.43±0.7 2.41 
 Lightlake 2 28 20 2 4.0/0.2  55 0.33 (0.1, 0.5) 2.09b 6.63±2.3 9.91±2.7 9.82±2.7 1.66±0.6 2.48±0.7 2.46 
 Lightlake 2 28 40 1 4.0/0.1  49 0.50 (0.2, 1.0) 2.00b 5.34±2.4 8.87±3.3 8.78±3.3 1.34±0.6 2.22±0.8 2.20 
 Lightlake 2 28 40 2 8.0/0.2  45 0.33 (0.2, 1.0) 1.91b 10.3±4.0 16.1±3.8 15.9±3.8 1.29±0.5 2.01±0.5 1.99 
 Euro-Celtique 11 20 2 8.0/0.4  22)a, d  0.34±0.2 9.48±3.9f 12.8±4.5 22.0±4.2f 20.1±4.9 1.60a 2.76a 2.51a 
 Euro-Celtique 12 40 2 16.0/0.4 (21)a, d  0.39±0.2 9.09±2.7f 18.3±7.5 42.8±10.6f 32.8±10.2 1.14a 2.67a 2.05a 
SL Euro-Celtique 11 16  16.0/1.0 (1)a, d  3.91±10.6 1.13±0.2f 0.90±0.4 1.50±0.4f 2.67±1.8 0.06a 0.09a 0.17a 
Annotations: Values for tmax, Cmax, AUC, t1/2 denote mean ±SD, except for values in italics. Values in italics denote median ±SD or median (min, max). Inconsistent information between the 
patent and the PK data whether the formulation contained10mg/ml Naloxone HCl dihydrate or 10mg/ml Naloxone HCl. Dose-adjusted values (per mg) in table are based on Naloxone HCl.  a 
calculated values; b harmonized mean; c re-administration after 5 minutes; d calculated F and FIM values based on AUC0-∞; e sample size = 3; f sample size = 4; NA = not available; IV = 
Intravenous; IM = Intramuscular; SQ = Subcutaneous; IN = Intranasal; SL = Sublingual. 
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Figure 2 | AUC0-∞, Cmax and tmax plotted by volume and dose 
  
Figure 1 | PRISMA diagram of PatentScope search 
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Figure 2 | PRISMA diagram of PubMed search 
Studies screened for title and abstract  
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Figure 3 | AUC0-∞, Cmax and tmax plotted by volume and dose 
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